GI Cancer Clinical Roundup
(Yahoo! Finance) Nov 20, 2020 - Study results show diagnostic accurately detects colorectal cancer and precancerous adenomas with high sensitivity.
(ESMO Asia 2020) Nov 20, 2020 - Envafolimab (KN035), a novel PD-L1 antibody, demonstrated robust anti-tumour activity and was safe in patients with diverse advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) tumours, according to findings presented at the ESMO Asia Virtual Congress 2020.
(Yahoo! Finance) Nov 13, 2020 - New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC. Test has potential to outperform current screening modalities for early stage HCC within high risk populations.
(Regenstrief [Indianapolis, IN]) Nov 10, 2020 - Regenstrief Institute and Indiana University School of Medicine research scientists have developed and tested one of the first U.S.-based models to predict personal risk for advanced precancerous polyps and colon cancer in average risk individuals.
(Northwestern Now) Oct 30, 2020 - Patients of more technically skilled surgeons, as assessed by review of operative video, have better long-term survival after surgery for the treatment of colon cancer, reports a new Northwestern Medicine study.
Patients whose surgery was performed by a highly skilled surgeon had a 70 percent lower...
(Br J Cancer) - 2020-11-19
(Br J Cancer) - 2020-11-18
(Clin Cancer Res) - 2020-11-17
(J Natl Cancer Inst) - 2020-11-02
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer
Treating inoperable liver cancer has come a long way in the last 15 years from the standard treatment known as TACE. Read a summary of new clinical guidance on unresectable HCC to find out about current systemic treatment options available, learn what a working group has to say about when to use TACE, and more.